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Abstract
Background:  The  incidence  of  surgical  site  infection  (SSI)  in  breast  surgery  has  been  higher
than expected,  considering  this  is  a  clean  surgical  procedure.  Few  studies  have  reported  an
incidence  of  less  than  5.0%  and  most  publications  report  an  incidence  of  between  10.2%  and
30.0%.
Objective:  To  estimate  the  incidence,  associated  factors  and  interval  free  from  infection  at
30 days  postsurgery  in  women  who  underwent  oncological  and  reconstructive  breast  surgery.
Methods: Prospective  cohort  study  of  women  with  breast  cancer  who  underwent  conservative
or radical  breast  surgery  at  a  reference  medical  center  in  Medellín,  Colombia.  The  outcomes
were SSI  and  time  to  the  event.  The  survival  analysis  of  freedom  from  infection  was  performed
using the  Kaplan  Meier  method  and  the  Cox  proportional  hazard  model  for  multivariate  analysis.
Results: Of  the  308  consecutive  surgical  breast  oncology  procedures  performed,  161  (52.3%)
were quadrantectomies  and  147  (47.7%)  were  mastectomies,  with  an  SSI  incidence  of  16.2%
(50 cases).  The  associated  risk  factors  were  seroma--hematoma,  which  occurred  in  79  (25.6%)
cases, hazard  ratio  (HR)  2.7  (95%  CI  1.5--4.9);  and  the  presence  of  drainage  devices,  HR  5.6
(95% CI  2.2--14.3).  The  median  time  to  the  development  of  SSI  was  16  days.Please  cite  this  article  in  press  as:  Gil-London˜o  J-C,  et  al.  Surgical  site  infection  after  breast  cancer  surgery  at  30  days
and  associated  factors.  Infectio.  2016.  http://dx.doi.org/10.1016/j.infect.2016.04.003
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Conclusion:  Our  study  shows  that  the  presence  of  postoperative  seroma--hematoma  and  long-
term drainage  device  use  were  independent  risk  factors  for  SSI  in  oncological  breast  surgery.
© 2016  ACIN.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open  access  article  under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE
Cáncer  de  mama;
Infección  asociada  a
la  atención  en  salud;
Infección  del  sitio
operatorio
Infección  del  sitio  operatorio  en  cirugía  oncológica  de  mama  a  30  días  y  factores
asociados
Resumen
Antecedentes:  La  incidencia  de  infección  del  sitio  operatorio  (ISO)  en  cirugía  de  mama  ha
sido mayor  de  lo  esperado,  considerando  este  como  un  procedimiento  quirúrgico  limpio.  Pocos
estudios han  reportado  una  incidencia  menor  del  5,0%  y  la  mayoría  de  publicaciones  la  ubican
entre 10,2  y  30,0%.
Objetivo:  Estimar  la  incidencia,  los  factores  asociados  y  el  intervalo  libre  de  infección  a  30  días,
en las  mujeres  que  se  sometieron  a  cirugía  oncológica  y  reconstructiva  de  mama.
Métodos: Estudio  de  cohorte  prospectivo  en  mujeres  con  cáncer  de  mama,  que  se  sometieron
a cirugía  de  mama  conservadora  o  radical  en  un  centro  médico  de  referencia  de  Medellín,
Colombia.  Los  resultados  fueron  infección  del  sitio  operatorio  y  tiempo  al  evento.  El  análisis
de supervivencia  libre  de  infección  se  realizó  con  el  método  de  Kaplan  Meier  y  el  modelo
multivariado  de  riesgos  proporcionales  de  Cox.
Resultados:  Seguimiento  a  308  procedimientos  quirúrgicos  oncológicos  de  mama  consecutivos;
161 (52,3%)  fueron  cuadrantectomías  y  147  (47,7%)  mastectomías,  con  una  incidencia  de  ISO
de 16,2%  (50  casos).  Los  factores  de  riesgo  asociados  fueron:  seroma-hematoma  79  (25,6%),  HR
2,7 (IC  95%:  1,5;  4,9)  y  la  presencia  de  dispositivos  de  drenaje,  HR  5,6  (IC  95%  2,2;  14,3).  El
tiempo medio  para  el  desarrollo  de  SSI  fue  de  16  días.
Conclusión:  Nuestro  estudio  mostró  que  la  presencia  de  seroma  hematoma  posoperatorios  y  el
uso extendido  de  dispositivos  de  drenaje  fueron  factores  independientes  para  la  presentación
de infección  del  sitio  operatorio  en  cirugía  oncológica  de  mama.
© 2016  ACIN.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un  art´ıculo  Open  Access  bajo  la  CC
BY-NC-ND licencia  (http://creativecommons.org/licencias/by-nc-nd/4.0/).
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reast  cancer  represents  10%  of  new  cancer  events  in  the
orld  every  year1;  It  is  the  main  cause  of  mortality  in  women
etween  35  and  64  years  old.2 In  Colombia,  it  is  the  second
alignant  tumor  in  women  and  causes  1,700  deaths  yearly.3
astectomy,  quadrantectomy  and  lymphadenectomy  are  the
ost  frequent  procedures  in  breast  oncology  surgery.4,5
Reported  incidences  of  surgical  site  infection  (SSI)  vary
etween  10.2%  and  30.0%  and  are  higher  than  those  of
ther  clean  surgeries  (2.07%-3.9%).4,6--13 The  incidence  of  SSI
n  breast  surgeries  with  prosthesis  range  between  2.5  and
0.0%.14
Our  study  estimates  the  incidence,  associated  factors  and
ime  freedom  of  infection  at  30-days  after  breast  oncology
urgery  with  or  without  immediate  reconstruction.
ethods
his  was  a  prospective  cohort  study  of  308  patients  withPlease  cite  this  article  in  press  as:  Gil-London˜o  J-C,  et  al.  Sur
and  associated  factors.  Infectio.  2016.  http://dx.doi.org/10.1
reast  oncology  surgeries  at  Clínica  Las  Américas,  Medellín
olombia,  between  August  and  December  2011.  The  proce-
ures  were  radical  (complete  mastectomy  with  or  without
xillary  lymphadenectomy,  and  with  or  without  immediate
p
c
o
oeconstruction),  or  conservative  (quadrantectomy,  tumorec-
omy).
Inclusion  Criteria:  Women  18  years  old  or  older  who
nderwent  elective  breast  oncology  surgery,  with  or  without
mmediate  reconstruction.
Exclusion  Criteria:  Active  breast  infection  at  or  near  the
ntended  surgical  area  at  time  of  surgery.
The  post-operative  follow  up  was  conducted  by  a  trained
eam  of  physicians  and  nurses  and  begun  with  a  medical
xamination  in  the  ﬁrst  week  after  surgery;  patients  had
dditional  medical  and  nursing  controls  if  they  needed;  at
0  days  after  the  procedure,  patients  had  a  telephone  follow
p  with  a  pre-structured  format  and  a  new  medical  control
as  schedule  when  it  was  necessary.
Data  collecting  instruments  had  three  moments:  pre-
perative  evaluation,  intra-operative  follow  up  and  post-
perative  follow  up.  The  researchers  did  not  modify  the
outine  patient  medical  care.  Socio-demographic  variables
ere  evaluated  (age,  socioeconomic  status,  educational
evel,  type  of  health  insurance);  medical  and  surgical
istory,  comorbidities  and  previous  treatments;  currentgical  site  infection  after  breast  cancer  surgery  at  30  days
016/j.infect.2016.04.003
rocedure  data  including  antibiotic  prophylaxis  (if  was  indi-
ated),  surgery  executed,  type  of  surgical  wound,  duration
f  surgery  in  minutes  and  use  of  drainage  devices.  The  post-
perative  follow  up  included  medical  evaluation,  wound
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healing,  antibiotic  use,  drainage  device  used  (in  days),  hos-
pital  readmission,  surgical  re-interventions  related  to  the
index  procedure,  presence  of  seroma--hematoma  and  SSI.
The  adequate  prophylactic  antibiotic  treatment  was
deﬁned  as  the  administration  of  cefazoline,  clindamycin  or
vancomycin,  15--60  min  before  surgical  incision,  according
to  our  institutional  protocol.
The  study  was  approved  by  the  Bioethics  Committee  of
University  of  Antioquia  and  the  Research  Ethics  Committee
of  Clínica  Las  Américas.
The  primary  outcome  was  SSI  cases,  deﬁned  according
to  the  criteria  of  the  Centers  for  Disease  Control,  ver-
sion  2008.8 And  secondary  outcomes  were  seromas  and
hematomas  diagnosed  by  attending  physicians.
Statistical analysis
Qualitative  variables  were  described  by  proportions  and
its  independency  relationships  were  established  with  Chi-
square  test.  For  quantitative  variables,  the  mean,  measures
of  central  tendency  and  mean  differences  were  determined.
The  Relative  Risk  (RR)  was  calculated  for  the  incidence  of
SSI,  according  to  type  of  surgery.  Confusion  and  interaction
were  also  evaluated.  Cox  proportional-hazards  regression
model  was  used  to  estimate  the  Hazard  Ratios  (HR)  of  SSI  by
the  stepwise  method,  when  the  Log  Rank  Test  p  value  was
<0.25.  The  time  to  event  was  the  number  of  days  between
surgical  intervention  until  ﬁrst  infection  symptoms  in  a  range
of  30  days  postoperative.  Deaths  unrelated  to  SSI  and  losses
of  follow  up  were  considered  as  censures.  The  statistical
analysis  was  performed  using  the  PASW  Statistics  (SPSS  Inc.,
Version  18.0.  Chicago:  SPSS  Inc).
Results
The  SSI  rate  was  16.2%  (50/308);  the  infection  was  classiﬁed
as  superﬁcial  in  36  cases  (11.7%),  deep  in  14  (4.5%)  and  none
organ/space  SSI  (Fig.  1).  The  median  time  to  SSI  diagnosis
after  surgical  intervention  was  16  days  (IQR:  10--22).  Nine
of  40  patients  with  immediate  breast  reconstruction  were
diagnosed  with  SSI  (22.5%).
There  were  no  signiﬁcant  differences  in  socio-
demographic  variables  among  the  patients  (Table  1).
Previous  history  of  breast  surgery  was  present  in  63
women  (20.5%),  diabetes  mellitus  in  34  (11%)  and  obe-
sity/overweight  in  161  (52.3%).  The  delimitation  of  surgical
ﬁeld  was  performed  in  211  patients  (69%)  employing  sentinel
lymph  node  in  130  (61.6%),  sentinel  node  plus  self-retaining
anchor  wire  in  55  (26.1%)  and  only  self-retaining  anchor
wire  in  26  (12.3%).  Antibiotic  prophylaxis  was  administered
to  307  patients  (99.7%),  it  was  adequate  in  77.9%;  no  dif-
ferences  were  found  between  types  of  surgery.  The  overall
median  time  of  surgery  length  was  90  min,  interquartile
ranges  (IQR)  65--120;  for  conservative  surgery  it  was  70  min
(IQR:  55--97.5),  and  for  radical  surgery,  115  min  (IQR:
85--135).
Postoperative  hospitalization  was  one  day  in  199  (64.6%).Please  cite  this  article  in  press  as:  Gil-London˜o  J-C,  et  al.  Sur
and  associated  factors.  Infectio.  2016.  http://dx.doi.org/10.10
The  median  time  until  the  ﬁrst  medical  evaluation  after
hospital  discharge  was  9  days,  (IQR):  8--16.
The  postoperative  follow  up  was  performed  by  a  physi-
cian  in  217  patients  (70.1%),  by  a  physician  and  a  nurse  in  58
o
d
t
sigure  1  Cohort  of  breast  cancer  surgery.  Clinica  Las
mericas, Medellin,  Colombia  2011--2.
18.8%)  and  by  a  nurse  alone  in  12  (3.9%).  All  patients  were
live  at  the  end  of  follow  up.
Twelve  patients  had  readmission  (3.89%)  due  to  SSI,  with
 median  readmission  time  after  surgery  of  18  days.
Drains  in  situ  were  used  during  a  median  of  16  days  (IQR:
2--22).  Seromas--hematomas  were  detected  in  79  cases
25.6%)  and  of  these,  33  (41.8%)  were  drained.  Inadequate
anipulation  of  drain  in  situ  was  observed  in  12.2%  of  cases.
The  axillary  node  clearance  was  a  risk  factor  in  the  bivari-
te  analysis,  RR  2.8  (95%  CI:  1.67--4.74;  p  value  <0.01),  but  it
as  not  statistically  signiﬁcant  in  the  multivariable  model.
he  delimitation  of  surgical  ﬁeld  was  a  protective  factor  in
he  bivariate  analysis,  RR:  0.49  (95%  CI:  0.3--0.82;  p  =  0.006)
Table  2).
In patients  with  prolonged  postoperative  drain  device
SI  was  higher  than  those  without  drainage,  HR:  5.6  (95%
I  2.2--14.3,  p  <  0.000).  The  infection  proportion  with  sili-
one  suction  drain  (Jackson  Pratt®)  was  6.7%  versus  27.0%
ith  polyvinyl  suction  drain  (Hemovac®)  and  it  was  higher
n  patients  with  seroma--hematoma,  HR:  2.7  (95%  CI:
.55--4.96,  p  <  0.001)  (Fig.  2).
iscussion
SI  is  one  of  the  most  important  complications  of  breastgical  site  infection  after  breast  cancer  surgery  at  30  days
16/j.infect.2016.04.003
ncology  surgery  that  frequently  occurs  after  patient
ischarge.  In  this  study  the  most  important  risk  fac-
ors  were  prolonged  postoperative  drain  device  and
eroma--hematoma.4,9,10
Please  cite  this  article  in  press  as:  Gil-London˜o  J-C,  et  al.  Sur
and  associated  factors.  Infectio.  2016.  http://dx.doi.org/10.1
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Table  1  Baseline  characteristics.
Variable  Mastectomy  Quadrantectomy  Overall  (%)  p
n (%)  n  (%)
Surgery  Patients  147  (47.7)  161  (52.3)  308  (100.0)
Socioeconomic
status
Low SES  and  high  middle  SES 111  (78.1) 112  (71.3) 223  (74.6)  0.17
High SES 31  (21.8) 45  (28.6) 76  (25.4)
BMI Underweight  5  (3.4)  2  (1.25)  7  (2.3)  0.359
Overweight  50  (34.9)  55  (34.3)  105  (34.6)
Obese 22  (15.3)  34  (21.2)  56  (18.4)
Normal 66  (46.1)  69  (43.1)  135  (4.5)
Diabetes mellitus Yes  16  (10.8)  18  (11.1)  34  (11.0)  0.934
No 131  (89.1)  143  (88.8)  274  (88.9)
Previous
radiotherapy
Yes 8  (5.4)  5  (3.1)  13  (4.2)  0.308
No 139  (94.5)  156  (96.8)  295  (95.8)
Previous
chemotherapy
Yes 26  (17.6)  14  (8.6)  40  (12.9)  0.019
No 121  (82.3)  147  (91.3)  268  (87.0)
Educational  level <=5  years  of  academic  education  87  (61.2)  90  (58.0)  177  (59.5)  0.57
>5 years  of  academic  education  55  (38.7)  65  (41.9)  120  (40.4)
Adequate antibiotic
prophylaxis
No  34  (23.1)  34  (21.1)  68  (22.0)  0.671
Yes 113  (76.8)  127  (78.8)  240  (77.9)
Type of  surgery With  reconstructive  surgery  38  (25.8)  2  (1.2)  40  (12.9)  <0.01
W/O reconstructive  surgery  109  (74.1)  159  (98.7)  268  (87.0)
Surgeon specialty Oncologist  76  (51.7)  90  (55.9)  166  (53.8)  0.263
Gynecologist  2  (1.3)  6  (3.7)  8  (2.5)
Mastologist  69  (46.9)  65  (40.3)  134  (43.5)
Axillary limph
node  clearance
Yes  82  (55.7)  31  (19.2)  113  (36.7)  <0.01
No 65  (44.2)  130  (80.7)  195  (63.3)
Skin antiseptic
cleanser
Iodine  antiseptic  112  (76.1)  120  (74.5)  232  (75.3)  0.73
Chlorhexidine  35  (23.8)  41  (25.4)  76  (24.7)
Seroma or
hematoma
Yes  41  (27.8)  38  (23.6)  79  (25.6)  0.38
No 106  (72.1)  123  (76.3)  229  (74.4)
Use of  drainage
systems
Yes  146  (81.1)  34  (18.8)  180(58.4)  <0.01
No 1  (0.78)  127  (99.2)  128  (41.5)
Type of  drain Hemovac  132  (90.4)  33  (97.0)  165  (91.6)  <0.01
Jackson Prat 14  (9.5) 1  (2.9) 15  (8.3)
SSI Yes 34
No 113
Survival functions
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Figure  2  Seroma--hematoma  versus  time  without  infection.
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The  persistence  of  a  drain  in  situ  was  a  risk  fac-
or  for  SSI.  The  extended  persistence  of  drains,  washing
ubes  to  remove  ﬁbrin  clots,  connection  and  disconnection
f  proximal  tubes  without  standardized  aseptic  practices
ncrease  the  risk  of  infection.4,11--14 Some  authors  recom-
end  removal  of  the  drain  when  drainage  volume  becomes
ess  than  30--50  ml/day  during  48  h;  others  recommend  their
emoval  at  ﬁxed  time  intervals  (5--7  days);  in  our  study,  the
edian  time  of  drainage  was  16  days4,7,14--18.  Future  studies
hould  be  directed  to  remove  the  drain  in  less  time.
In  the  postoperative  period,  the  most  frequent
omplications  in  breast  oncology  surgery  were
eroma--hematoma  formation,  with  higher  risk  of  SSI
or  seroma  and  for  hematoma,  increased  the  mortality
nd  length  of  hospital  stay.12,19 In  our  study,  postoperative
eroma-hematoma  incidence  was  25.6%  while  in  others  it
anged  from  18%  to  59%.6,14,15,20--22 A  case--control  studygical  site  infection  after  breast  cancer  surgery  at  30  days
016/j.infect.2016.04.003
howed  that  seroma--hematoma  puncture  and  drainage
ere  risk  factors  for  SSI.20
The  risk  of  developing  SSI  was  signiﬁcantly  higher
or  mastectomies  vs  conservative  surgeries  in  our  study;
ARTICLE IN PRESS+ModelINFECT-113; No. of Pages 6
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Table  2  SSI  in  breast  cancer  surgery  -  bivariate  analyses.
Variable  SSI  n  =  50  Overall  Value  RR  (IC  95%)
(% incidence)  n  =  308  p
Socioeconomic
status
Middle  SES  and  low  SES  40  (81.6)  223  0.2151  1.51  (0.77--2.97)
High SES 9  (18.3) 76
Mellitus  diabetes Yes 8  (16.0) 34  0.22  1.50  (0.78--2.99)
No 42  (84) 274
BMI Obesity  12  (21.4) 56  0.2 1.52  (0.79--2.92)
Overweight  17  (16.2)  105  0.64  1.15  (0.62--2.10)
Thinness 1  (14.3)  7  0.41  0.46  (0.06--3.27)
Normal 19  (14.4)  132
Educational  level <=5  years  of  academic  education  28  (59.5)  177  0.99  0.99  (0.58--1.70)
>5 years  of  academic  education  19  (40.4)  120
Surgery Mastectomy  34  (68.0)  147  0.001  2.32  (1.34--4.03)
Cuadrantectomy  16  (32.0)  161
Delimitation  of
surgical  ﬁeld
Yes  26  (52.0)  211  0.006  0.49  (0.30--0.82)
No 24  (48.0)  97
Axillary node
clearance
Yes  31  (62.0)  113  <0.01  2.81  (1.67--4.74)
No 19  (38.0)  195
Hair removal Yes  4  (8.0)  16  0.32  1.50  (0.65--3.86)
No 46  (92.0)  292
Skin antiseptic
cleanser
Iodine  antiseptic  38  (76.0)  232  0.9  1.03  (0.57--1.88)
Chlorhexidine  12  (24.0)  76
Timing of  antibiotic
prophylaxis
Intraoperative  1  (0.5)  4  0.0017  1.77  (0.29--10.65)
>61 min  after  starting  surgery  12  (24.0)  53  0.21  1.60  (0.75--3.43)
30 min  before  surgery  10  (20.0)  71
Between  31  and  60  min  before  surgery  27  (54.0)  179  0.84  1.07  (0.54--2.09)
Adequate antibiotic
prophylaxis
No  15  (30.0)  68  0.14  1.51  (0.88--2.59)
Yes 35  (70.0)  240
Use of  drainage
systems
Yes  45  (90.0)  178  <0.01  6.57  (2.68--16.09)
No 5  (10.0)  130
Manipulation  of
drainage  systems
Yes  11(24.4)  22  <0.01  2.26  (1.35--3.78)
No 34(75.5)  154
Seroma or
hematoma
Yes  25  (50.0)  79  <0.01  2.80  (1.77--4.74)
No 25  (50.0) 229
Seroma  drainage Yes  15(60.0)  35  0.05  1.88  (0.96--3.66)
No 10(40.0) 44
Surgeon  specialty Oncologist  31  (62.0) 166  0.29  1.31  (0.78--2.22)
Gynecologist  0  (0.0) 8  0.79 0.78  (0.11--5.20)
Mastologist  19  (38.0)  134
s
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Eother  reports  showed  SSI  incidences  of  38.3%  and  18%
respectively.11 Studies  with  one  year  follow  up  in  breast
surgeries  with  immediate  reconstruction  reported  similar
incidences  of  SSI  (2.5--30%).6--8
Wire  localization  delimitation  of  the  surgical  ﬁeld  and
radiocoloid  injection  before  surgery  showed  a  protective
association;  the  limitation  of  intervention  area  decreases
the  risks  of  postoperative  adverse  events.  The  axillary
node  lymphadenectomy  showed  statistical  differences  in  the
development  of  infection.  These  ﬁndings  are  similar  to  other
published  reports.14--23
Follow-up  was  completed  in  a  high  proportion  of  patients,
this  is  strength  and  it  was  possible  compared  preoperative,Please  cite  this  article  in  press  as:  Gil-London˜o  J-C,  et  al.  Sur
and  associated  factors.  Infectio.  2016.  http://dx.doi.org/10.10
intraoperative  and  postoperative  risk  factor.
The  most  important  risk  factors  mentioned  in  the  liter-
ature  were  evaluated.  Next  studies  should  appraise  shaving
of  patients  at  home  and  their  relationship  with  SSI.  The
P
f
otrengthening  of  postoperative  epidemiological  surveillance
ystems,  the  use  of  silicone  drains  and  sterile  techniques
o  manipulation  of  tube11,13,14 are  practical  tools  to  evalu-
te  the  reduction  in  seroma--hematoma  formation  and  drain
ime  in  other  studies.
In  conclusion,  our  study  shows  that  presence  of  postop-
rative  seroma--hematoma  and  long  time  drain  device  were
ndependent  risk  factors  for  SSI  on  oncology  breast  surgery.
hese  results  should  encourage  further  studies  on  tools  to
elp  remove  the  drains  in  less  time  and  avoid  the  formation
f  seromas  and  hematomas.
thical disclosuresgical  site  infection  after  breast  cancer  surgery  at  30  days
16/j.infect.2016.04.003
rotection  of  people  and  animals.  The  authors  state  that
or  this  investigation  have  not  been  performed  experiments
n  humans  or  animals.
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